IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 13.1 SEK 8.26% Market Closed
Market Cap: 678.4m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IRLAB Therapeutics AB
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Total Current Liabilities
kr36.7m
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Total Current Liabilities
kr429.8m
CAGR 3-Years
52%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Total Current Liabilities
kr403.3m
CAGR 3-Years
27%
CAGR 5-Years
26%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Total Current Liabilities
kr357.1m
CAGR 3-Years
61%
CAGR 5-Years
77%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Total Current Liabilities
kr20.5m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Total Current Liabilities
kr23.2m
CAGR 3-Years
15%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
No Stocks Found

IRLAB Therapeutics AB
Glance View

Market Cap
679.5m SEK
Industry
Pharmaceuticals

IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

IRLAB A Intrinsic Value
16.06 SEK
Undervaluation 18%
Intrinsic Value
Price

See Also

What is IRLAB Therapeutics AB's Total Current Liabilities?
Total Current Liabilities
36.7m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Total Current Liabilities amounts to 36.7m SEK.

What is IRLAB Therapeutics AB's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
24%

Over the last year, the Total Current Liabilities growth was 14%. The average annual Total Current Liabilities growth rates for IRLAB Therapeutics AB have been 21% over the past three years , 24% over the past five years .

Back to Top